$39.41
2.27%
NYSE, Sep 17, 11:03 am EDT. Market open.
ISIN
US8816242098
Symbol
TEVA

Teva Pharmaceutical Industries Limited Sponsored ADR Target price 2026 - Analyst rating & recommendation

Teva Pharmaceutical Industries Limited Sponsored ADR Classifications & Recommendation

Buy
86%
Hold
14%

Teva Pharmaceutical Industries Limited Sponsored ADR Price Target

Target Price $11.12
Price $38.53
Deviation
Number of Estimates 3
3 Analysts have issued a price target Teva Pharmaceutical Industries Limited Sponsored ADR 2027 . The average Teva Pharmaceutical Industries Limited Sponsored ADR target price is $11.12. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Teva Pharmaceutical Industries Limited Sponsored ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Teva Pharmaceutical Industries Limited Sponsored ADR stock has an average upside potential 2027 of . Most analysts recommend the Teva Pharmaceutical Industries Limited Sponsored ADR stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion $ 17.26 17.01
4.32% 1.43%
EBITDA Margin 29.78% 25.90%
6.03% 13.04%
Net Margin 8.17% 13.93%
182.47% 70.50%

7 Analysts have issued a sales forecast Teva Pharmaceutical Industries Limited Sponsored ADR 2026 . The average Teva Pharmaceutical Industries Limited Sponsored ADR sales estimate is

$17.0b
unlock
. This is
1.76% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$17.5b 1.18%
unlock
, the lowest is
$16.3b 5.69%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $17.3b 4.32%
2026
$17.0b 1.43%
unlock
2027
$17.7b 3.97%
unlock
2028
$18.5b 4.47%
unlock
2029
$18.9b 2.18%
unlock
2030
$19.8b 5.04%
unlock
2031
$20.8b 5.00%
unlock
2032
$21.8b 4.81%
unlock
2033
$22.5b 3.29%
unlock

6 Analysts have issued an Teva Pharmaceutical Industries Limited Sponsored ADR EBITDA forecast 2026. The average Teva Pharmaceutical Industries Limited Sponsored ADR EBITDA estimate is

$4.4b
unlock
. This is
31.10% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$4.6b 36.04%
unlock
, the lowest is
$4.2b 25.24%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $5.1b 10.61%
2026
$4.4b 14.30%
unlock
2027
$5.7b 30.12%
unlock
2028
$6.3b 9.54%
unlock
2029
$6.4b 2.50%
unlock
2030
$6.9b 6.65%
unlock
2031
$7.2b 5.46%
unlock
2032
$7.6b 4.77%
unlock
2033
$7.8b 2.41%
unlock

EBITDA Margin

2025 29.78% 6.03%
2026
25.90% 13.04%
unlock
2027
32.41% 25.14%
unlock
2028
33.98% 4.84%
unlock
2029
34.09% 0.32%
unlock
2030
34.61% 1.53%
unlock
2031
34.77% 0.46%
unlock
2032
34.75% 0.06%
unlock
2033
34.46% 0.83%
unlock

6 Teva Pharmaceutical Industries Limited Sponsored ADR Analysts have issued a net profit forecast 2026. The average Teva Pharmaceutical Industries Limited Sponsored ADR net profit estimate is

$2.4b
unlock
. This is
235.56% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$2.5b 248.26%
unlock
, the lowest is
$2.3b 220.19%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $1.4b 186.03%
2026
$2.4b 68.02%
unlock
2027
$3.7b 54.32%
unlock
2028
$4.1b 13.25%
unlock
2029
$4.4b 5.14%
unlock
2030
$4.9b 13.20%
unlock
2031
$5.1b 4.30%
unlock
2032
$5.6b 9.36%
unlock
2033
$6.0b 6.24%
unlock

Net Margin

2025 8.17% 182.47%
2026
13.93% 70.50%
unlock
2027
20.67% 48.38%
unlock
2028
22.41% 8.42%
unlock
2029
23.06% 2.90%
unlock
2030
24.85% 7.76%
unlock
2031
24.68% 0.68%
unlock
2032
25.76% 4.38%
unlock
2033
26.49% 2.83%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ 1.21 2.03
183.45% 67.77%
P/E 18.95
EV/Sales 3.41

6 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast for earnings per share. The average Teva Pharmaceutical Industries Limited Sponsored ADR EPS is

$2.03
unlock
. This is
238.33% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$2.11 251.67%
unlock
, the lowest is
$1.94 223.33%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $1.21 183.45%
2026
$2.03 67.77%
unlock
2027
$3.14 54.68%
unlock
2028
$3.55 13.06%
unlock
2029
$3.74 5.35%
unlock
2030
$4.23 13.10%
unlock
2031
$4.41 4.26%
unlock
2032
$4.82 9.30%
unlock
2033
$5.13 6.43%
unlock

P/E ratio

Current 64.22 148.33%
2026
18.95 70.49%
unlock
2027
12.28 35.20%
unlock
2028
10.84 11.73%
unlock
2029
10.31 4.89%
unlock
2030
9.11 11.64%
unlock
2031
8.73 4.17%
unlock
2032
7.99 8.48%
unlock
2033
7.52 5.88%
unlock

Based on analysts' sales estimates for 2026, the Teva Pharmaceutical Industries Limited Sponsored ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.35 47.58%
2026
3.41 1.79%
unlock
2027
3.28 3.82%
unlock
2028
3.14 4.28%
unlock
2029
3.07 2.13%
unlock
2030
2.93 4.80%
unlock
2031
2.79 4.76%
unlock
2032
2.66 4.59%
unlock
2033
2.57 3.19%
unlock

P/S ratio

Current 2.60 91.24%
2026
2.65 1.79%
unlock
2027
2.55 3.82%
unlock
2028
2.44 4.28%
unlock
2029
2.39 2.13%
unlock
2030
2.27 4.79%
unlock
2031
2.16 4.76%
unlock
2032
2.07 4.59%
unlock
2033
2.00 3.19%
unlock

Current Teva Pharmaceutical Industries Limited Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
Locked
Locked Nov 06 2025
JP Morgan
Locked
Locked
Locked Oct 03 2025
UBS
Locked
Locked
Locked Sep 24 2025
UBS
Locked
Locked
Locked Jun 26 2025
Goldman Sachs
Locked
Locked
Locked Jun 06 2025
Truist Securities
Locked
Locked
Locked May 28 2025
Analyst Rating Date
Locked
JP Morgan:
Locked
Locked
Nov 06 2025
Locked
JP Morgan:
Locked
Locked
Oct 03 2025
Locked
UBS:
Locked
Locked
Sep 24 2025
Locked
UBS:
Locked
Locked
Jun 26 2025
Locked
Goldman Sachs:
Locked
Locked
Jun 06 2025
Locked
Truist Securities:
Locked
Locked
May 28 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today